Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This study is a randomized, double-blind phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the consistency of three consecutive lots, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine of commercial scale in participants aged 40-65 years.
Epistemonikos ID: 769eb44cb887088b0614820b78ace75d4ba5df17
First added on: Oct 02, 2023